Activated ras is known to dysregulate TGF-b signaling by altering the expression of TGF-b type II receptor (RII). It is well documented that tumor cells harboring mutant ras are more resistant to radiation than cells with wild-type ras. In this study, we hypothesized that the use of farnesyltransferase inhibitor (FTI,832) may directly restore TGF-b signaling through RII expression via ras dependent or independent pathway leading to induction of radiation sensitivity. Two pancreatic cancer cell lines, BxPC-3 and MIA PaCa-2 were used in this study. FTI inhibited farnesylation of Ras protein more significantly in MIA PaCa-2 than BxPC-3 cells. In contrast, MIA PaCa-2 cells were resistant to radiation when compared to BxPC-3 cells. BxPC-3 cells were more resistant to FTI than MIA PaCa-2 cells. In combination treatment, no significant radiosensitizing effect of FTI was observed in BxPC-3 cells at 5 or 10 mM. However, in MIA PaCa-2 cells, a significant radiosensitizing effect was observed at both 5 and 10 mM concentrations (P40.004). The TGF-b effector gene p21 waf1/cip1 was elevated in combination treatment in MIA PaCa-2 but not in BxPC-3 cells. In MIA PaCa-2 cells, FTI induced TGF-b responsive promoter activity as assessed by 3TP-luciferase activity. A further induction of luciferase activity was observed in MIA PaCa-2 cells treated with radiation and FTI. Induction of TGF-b signaling by FTI was mediated through restoration of the RII expression, as demonstrated by RT -PCR analysis. In addition, re-expression of RII by FTI was associated with a decrease in DNA methyltransferase 1 (DNMT1) levels. Thus, these findings suggest that the L-744,832 treatment restores the RII expression through inhibition of DNMT1 levels causing induction of TGF-b signaling by radiation and this forms a novel molecular mechanism of radiosensitization by FTI.
Introduction
The cytokine TGF-b plays a dual role in tumorigenesis. On one hand TGF-b inhibits the proliferation of normal epithelial, endothelial, and hematopoietic cells and thus is crucial for the homeostasis of these tissues (Alexandrow and Moses, 1995; Massague, 1990; Sporn and Roberts, 1990) . TGF-b signaling is lost in some cancers by mutational inactivation of TGF-b signaltransduction components. A substantial proportion of colorectal and pancreatic cancers harbor inactivating alterations due to mutations or down-regulation of expression in the genes encoding the TGF-b type II receptor (RII) or its mediators, Smad-2 and Smad-4 (Grady et al., 1999; Hahn et al., 1996; Markowitz et al., 1995) .
On the other hand, TGF-b can exacerbate the malignant phenotype at later stages of tumorigenesis (Cui et al., 1996; Reiss and Barcellos-Hoff, 1997) . TGF-b is abundantly expressed in various tumors of epithelial origin in which it can suppress immune surveillance, foster tumor invasion and promote the development of metastases. These effects become manifest in tumor cells that retain TGF-b receptors but have lost the capacity to respond to TGF-b with growth arrest. Such a state of altered TGF-b responsiveness is observed in ras-transformed cells (Basolo et al., 1994) . How oncogenic ras counteracts the growth inhibitory effects of TGF-b are unknown. Although oncogenic ras can prevent the anti-mitogenic effects of TGF-b signaling, TGF-b can potently overcome the mitogenic effects of ras-activating factors such as EGF in epithelial cells (Alexandrow and Moses, 1995; Massague, 1990; Sporn and Roberts, 1990) . It is well documented that oncogenic ras can enhance resistance to ionizing radiation through ras effector pathways Gupta et al., 2000 Gupta et al., , 2001 . And, oncogenic ras was found to inhibit TGF-b signaling by down regulating RII expression (Zhao and Buick, 1995) . Thus, blocking the function of oncogenic ras should restore RII expression and sensitize to the effects of radiation. Farnesyltransferase inhibitors (FTI) inhibit the farnesylation of the ras protein and abrogate membrane binding. In this study we demonstrate that FTI (L744,832) restored the RII expression and radiation-induced TGF-b signaling leading to enhanced radiosensitization. The restoration of RII expression by FTI was mediated through downregulation of DNA methyltransferase 1 (dnmt1) levels, since DMNT's are associated with methylation of DNA and RII expression is down-regulated due to promoter hypermethylation.
Results
FTI inhibited the farnesylation of Ras protein in BxPC-3 and MIA PaCa-2 cells
The incidence of K-ras oncogene mutations is significantly higher in pancreatic adenocarcinomas when compared to other human malignancies (Fralix et al., 2000) . The incidence of N-ras or H-ras mutation is frequently uncommon. Two pancreatic adenocarcinoma cell lines, one with wild-type K-ras (BxPC-3) and the other with mutant K-ras (MIA PaCa-2), were used to assess the effect of FTI on Ras farnesylation. In both cell lines, 5 or 10 mM of FTI inhibited the farnesylation of Ras after 24 h of exposure. Compared to BxPC-3 cells (Figure 1a ), MIA PaCa-2 cells showed stronger inhibition of farnesylation of Ras in response to 5 mM of FTI (Figure 1b ). These findings indicate that irrespective of K-ras mutational status, FTI was found to inhibit the farnesylation of Ras protein in pancreatic adenocarcinoma cells.
FTI additively enhanced the effects of radiation in MIA PaCa-2 cells It was recently shown that L-744,832 effectively growth inhibited five different pancreatic cancer cell lines and this inhibition was associated with post-translational processing of H-ras and N-ras but not K-ras (Song et al., 2000) . Since L-744,832 effectively inhibited the farnesylation of Ras, we performed clonogenic cell survival experiments to ascertain the response to FTI alone, radiation alone and in combination treatments in BxPC-3 and MIA PaCa-2 cells. For FTI treatment the D 0 was calculated as the FTI dose required to reduce the surviving fraction to 37%, indicative of single-event killing. In BxPC-3 cells, the D 0 was 412.5 mM of FTI dose, whereas in MIA Paca-2 cells, only 1.1 mM FTI dose was required (Figure 2a ). For radiation alone and radiation plus FTI, the SF 2 was calculated as the survival fraction of exponentially growing cells that were irradiated at the clinically relevant dose of 2 Gy. MIA PaCa-2 cells (SF 2 =0.57) were more radio-resistant in comparison to BxPC-3 cells (SF 2 =0.45), however when treated with radiation plus FTI at 5 or 10 mM, MIA PaCa-2 cells (SF 2 =0.12 (for 5 mM) and 0.04 (for 10 mM)) were significantly more sensitive (P50.004) when compared to the BxPC-3 cells (SF 2 =0.31 (for 5 mM) and 0.38 (for 10 mM)) (Figures 2b,c, Table 1 ). These observations imply that the FTI L-744,832 sensitized to the effects of radiation in MIA PaCa-2 cells but not in BxPC-3 cells.
Increased cell death in MIA PaCa-2 cells treated with FTI or FTI plus radiation
Having ascertained the radiosensitizing effects of FTI on clonogenic inhibition, we then performed TUNEL assay to determine the radiosensitizing effect of FTI on apoptosis. No differences in the incidence of apoptosis was observed in BxPC-3 and MIA PaCa-2 cells treated with radiation alone (Figure 3) . Induction of apoptosis in BxPC-3 cells treated with FTI or FTI plus radiation was lower when compared to MIA PaCa-2 cells treated with FTI or FTI plus radiation. These results indicate that MIA PaCa-2 cells are significantly sensitive to the radiosensitizing effects of FTI than BxPC-3 cells.
L-744,832 restores RII expression in MIA PaCa-2 cells L-744,832 inhibited the post-translational processing of H-ras and N-ras but not K-ras (Song et al., 2000) . Over expression of H-ras in rat intestinal epithelial cells caused enhanced resistance to TGF-b1 (Filmus et al., 1992) . In addition, nuclear run-on experiments showed down-regulation of RII receptor mRNA by H-ras oncogene (Simeone et al., 2000) . Since L-744,832 inhibited the post-translational processing of H-ras, it may be speculated that this FTI can cause a direct effect on RII expression and TGF-b signaling. The cell line BxPC-3 was not selected to test this hypothesis since this cell line lacks DPC-4 (Smad-4) (Simeone et al., 2000) an important downstream gene to mediate and MIA PaCa-2 cells (b) treated with 5 mM FTI using pan-ras antibody (OP22) that detects H-, N-and K-Ras proteins. Whole cell protein extracts were prepared from BxPC-3 and MIA PaCa-2 cells that were left untreated (UT), or exposed to 5 mM of FTI and incubated for the time interval indicated. Lines define the migration of unfarnesylated and farnesylated Ras protein. The blots were also probed with an antibody for b-actin as a loading control TGF-b signaling. However, we selected MIA PaCa-2 cells to test this speculation based on three important reasons. One, these cells are highly resistant to exogenous recombinant TGF-b1 protein (Freeman et al., 1995) . Secondly, these cells lack RII expression and devoid of TGF-b signaling . Finally, these cells are very sensitive to L-744,832. MIA PaCa-2 cells were left untreated or exposed to FTI, FTI plus radiation, FTI plus anti-TGF-b and FTI plus radiation plus anti-TGF-b. Three and 6 h after treatment, total RNA was isolated and RII expression was determined by 32 P-RT -PCR analysis. The FTI alone or FTI plus radiation caused an induction of RII expression (Figure 4a ). Interestingly, the levels of RII transcripts increased when exposed to anti-TGF-b antibody in the presence of FTI alone or FTI plus radiation ( Figure 4a ). These results strongly suggest that the FTI L744,832 has a regulatory effect on RII receptor expression.
Since FTI restored the RII mRNA expression, we further ascertained whether the effect of FTI was mediated at the RII promoter level. MIA PaCa-2 cells were transiently transfected with the RII-CAT reporter (Figure 5a ). These findings implicate that L744,832 re-establishes radiation-induced TGF-b signaling by restoring RII expression and enhances the effect of radiation. One way to determine whether radiation-induced expression of TGF-b results in increased TGF-b signaling, is to measure the expression of TGF-b target genes. p21 waf1/cip1 has been thoroughly studied and is inducible by p53 (el-Deiry et al., 1994) . It is also known that TGF-b signaling through a Smad signaling complex activates the transcription of target genes such as p21
waf1/cip1 and other CDK inhibitors, which are key effectors for TGF-b-mediated growth inhibition (Hu et al., 1998) . MIA PaCa-2 cells contain only one allele of p53 and this allele is mutated at codon 248 (Caldas et al., 1994) . Western blot analysis showed a basal level of p21 waf1/cip1 ( Figure 5b ). p21 waf1/cip1 was up-regulated in 6 h after radiation in 5 or 10 mM FTI treated MIA PaCa-2 cells, but not in MIA PaCa-2 cells treated with radiation alone (Figure 5b ). These data suggest that the lack of up-regulation of p21 
Restoration of RII expression by FTI is signaled via down-regulation of dnmt1
It was recently reported that treatment of MIA PaCa-2 cells with the DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, resulted in RII expression through increased transcription of Sp1 and its binding to RII promoter (Venkatasubbarao et al., 2001) . High levels of dnmt1 activity was found in many tumor cells in vitro (Kautiainen and Jones, 1986) and tumor cells in vivo (elDeiry et al., 1991). Interestingly activation of oncogenic ras signaling results in the induction of dnmt1 expression Rouleau et al., 1995) . It was reported that the ras-c-jun oncogenic signaling directly regulates the transcription of dnmt1 gene (Bigey et al., 2000) . Thus, elevated levels of dnmt1 are required to maintain ras-transformed phenotype, indicating that dnmt1 is an important down stream effector of ras oncogenic pathway . Based on these reports, in this study we hypothesized that FTI will have a direct effect in down regulating dnmt1 levels and this down regulation may release the repression that exists in the RII promoter. To test this, MIA PaCa-2 cells were left untreated or exposed to FTI or radiation or FTI plus radiation and total RNA and protein were isolated. RT -PCR analyses showed that FTI or FTI plus radiation significantly inhibited the expression of dnmt1 when compared to the untreated levels ( Figure  6a ). Western blot analysis showed a significant down regulation of dnmt1 protein in response to FTI or FTI plus radiation exposures (Figure 6b ). These findings suggest a causal link between the down-regulation of dnmt1 and upregulation of RII expression in response to FTI treatment.
Discussion
Activating mutations in the ras family stabilize the active ras in GTP-bound state, leading to increased cellular proliferation and oncogenic growth. These types of mutations are commonly identified in the carcinomas of the pancreas and colon. In addition to ras oncogene transformation potential, the oncogenic ras expression often causes increased radiation resistance in many tumor cell types (Bruyneel et al., 1993; Hermens and Bentvelzen, 1992; Miller et al., 1993) . Inhibiting oncogenic ras activity could reduce the resistance of tumor cells to radiation. Ras members usually transduce the oncogenic signal after a series of post-translational modifications that is initiated by farnesyltransferase. The post-translational modification results in the prenylation of the ras protein that in turn binds to the membrane to be active in transformation and proliferation (Kato et al., 1992) . The dissection of this ras signaling pathway led to the development of synthetic inhibitors to target enzymes that are involved in ras prenylation. Currently two such enzymes are in focus: farnesyltransferase and geranylgeranyltransferase. These inhibitors mimic the prenyl group substrate or the tetrapeptide recognition sequence on ras that is targeted by farnesyltransferase (known as CAAX motif; cysteine, aliphatic, aliphatic, X). Several studies have shown that inhibition of ras signaling alter the growth of pancreatic cancer cell lines (Leach et al., 1998; Shichinohe et al., 1996; Song et al., 2000) . In this study, we selected two pancreatic cancer cell lines: one with wild type K-ras and the other with mutant K-ras. Both cell lines showed inhibition of growth in response to the farnesyltransferase inhibitor, L744,832. However, the inhibition of growth was significantly pronounced in mutant K-ras MIA PaCa-2 cells when compared to the moderate effect of FTI in wild type K-ras BxPC-3 cells. This observation is supported by a recent study in which mutant pancreatic cancer cell lines such as Panc-1 and Capan-2 were more sensitive in the treatment of FTI than wild type K-ras BxPC-3 cells (Song et al., 2000) . However, it is clear from previous reports that FTI, L744,832 does not inhibit Kras oncogene function. These studies together indicate that the FTI, L744,832 may preferentially inhibit growth inhibition in mutant K-ras pancreatic cancer cells and this may not be directly linked to inhibition of K-ras oncogenic protein prenylation. The active signaling mediated through mutationactivated or oncogenic ras causes upregulation of prosurvival genes such as NF-kB (Finco et al., 1997) or other transcriptional factors such as ETS, c-jun and myc (Galang et al., 1994; Marte and Downward, 1997) . In addition, oncogenic ras is a potent down-regulator of pro-apoptotic and growth inhibitory signaling genes such as par-4 (Nalca et al., 1999) and TGF-b signaling cascade (Saha et al., 2001) . Thus, mutations in K-ras P-RT -PCR analysis of dnmt1. Total mRNA was isolated from MIA PaCa-2 cells that were left untreated (UT) or exposed to 5 Gy or FTI (10 mM) or FTI plus 5 Gy and incubated for 24 h. PCR was performed using the reverse transcribed cDNA products and specific 5'-end radiolabeled primers for dnmt1 gene and G6PDH. The products were electrophoresed on PAGE, dried and autoradiographed. (b) Western blot analysis was performed to detect DNMT1 protein expression in MIA PaCa-2 cells. Cells were left untreated (UT) or treated with 5 Gy or exposed to 5 Gy plus FTI (10 mM) and incubated for 24 h. The blots were probed with an antibody for DNMT1 (Imgenex, CA, USA) or b-actin (Sigma, St. Louis, MO, USA) pave the way for accelerated tumor progression in pancreatic tumors, through inhibition of pro-apoptotic and growth inhibitory signaling with simultaneous increase in pro-survival gene activity. Inhibition of TGF-b antiproliferative response by activated ras was found to be through suppression of Smad 2 or 3 nuclear translocation (Calonge and Massague, 1999) . In addition, accumulation of RII mRNA was found to be fivefold in ras expressing cells compared to control cells (Zhao and Buick, 1995) . MIA PaCa-2 cells lack RII expression and do not respond to TGF-b. Overexpression of RII in these cells restored TGF-b signaling and conferred enhanced radiation sensitivity (Ahmed et al., 2002) . Exposure to FTI L744,832, restored RII expression and TGF-b signaling in MIA PaCa-2 cells, suggesting that inhibition of activating functions of ras by FTI does cause a reversal in TGF-b response. This is supported by a recent study in which stimulation of transcription and protein expression of RII correlated with enhanced TGF-b response by FTI in mutant K-ras Panc-1 pancreatic cancer cells (Adnane et al., 2000) . Together, inhibition of complex oncogenic ras signaling by FTI can potentially inhibit the tumor growth via restoration of negative growth factor signaling such as TGF-b1.
One of the reasons for the absence of RII expression in MIA PaCa-2 cells was due to the reduced Sp-1 transcriptional activity and in addition hypermethylation of the RII promoter (Venkatasubbarao et al., 2001) . Methylation of promoters are directly linked to DNA methyltransferase enzyme levels (DNMT). Several reports have demonstrated elevated levels of DNMT expression and activity in tumors with oncogenic ras mutations Rouleau et al., 1995) . Thus, inactivation of pro-apoptotic and growth inhibitory genes by oncogenic ras may be directly linked to the elevated levels of DNMT that mediates the silencing of promoters through hypermethylation process. Since FTI L744,832 blocked the function of oncogenic ras and restored RII expression and since the RII promoter is prone to hypermethylation, we speculated that FTI may alter the DNMT levels to restore RII expression. Testing of this speculation in an MIA PaCa-2 cell model indicated that FTI L744,832 significantly down-regulated the mRNA and protein levels of DNMT-1. This down-regulation of DNMT-1 was associated with re-expression of RII suggesting that FTI mediated inhibition of oncogenic ras function may potentially release hypermethylation via down-regulation of DNMT-1. Thus, the FTI mediated restoration of TGF-b signaling through re-expression of RII via inhibition of DNMT-1 expression is a novel effect and this potentially sensitizes to the effects of ionizing radiation.
Materials and methods

Cell lines and treatments
Two pancreatic cancer cell lines (BxPC-3 and MIA PaCa-2) were used in this study. These cell lines were purchased from American Type Culture Collection (Rockville, MD, USA), and grown in DMEM with high glucose (Gibco -BRL) and supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 378C and 5% CO 2 . A 100 kV industrial X-ray machine (Phillips, Netherlands) was used to irradiate the cultures at room temperature. The dose rate with a 2 mm Be filter is *1.9 Gy/min at a focus-surface distance (FSD) of 30 cm. The peptidomimetic FTI L-744,832 targets the inhibition of ras farnesylation. The drug was dissolved in double distilled water to a final concentration of 1 mM. Stocks were stored at 48C and kept for no longer than 30 days.
Colony forming assay
For clonogenic cell survival studies, two different cell concentrations in quadruplet sets were used for each radiation dose, FTI treatment or in combination. Cell lines were left untreated or exposed to 1 -6 Gy dose of radiation or 2.5 to 12.5 mM FTI or for combination treatment, the FTI dose was 5 or 10 mM with 1 -6 Gy. In particular, for combination experiments, cells were treated with FTI and irradiated immediately. The drug was also present in the medium until the completion of the assay. After incubation for 12 or more days, each flask were stained with crystal violet and the colonies containing more than 50 cells were counted. The surviving fraction (SF) was calculated as a ratio of the number of colonies formed and the product of the number of cells plated and the plating efficiency. SF 2 is the survival fraction of exponentially growing cells that were irradiated at the clinically relevant dose of 2 Gy.
Quantification of apoptosis
Apoptosis was quantified by TUNEL staining. The ApopTag in situ apoptosis detection kit (Oncor, Gaithersburg, MD, USA), that detects DNA strand breaks by terminal transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) was used as described (Ahmed et al., 1997) . Briefly, cells were seeded in chamber slides and the next day they were exposed to 5 Gy dose of radiation. After 24 h and 48 h, the DNA was tailed with digoxigenin-dUTP and conjugated with an anti-digoxigenin fluorescein. The specimen was counter stained with propidium iodide and antifade. The stained specimen was observed in triple band-pass filter using a Nikon-microphot epifluorescence microscope. To determine the percentage of cells showing apoptosis, two experiments in total were performed, and approximately 1000 cells were counted in each experiment.
Western blot analysis
Total protein were extracted from untreated, 5 Gy, FTI plus 5 mM FTI, 5 Gy plus 10 mM FTI-exposed cultures at various time points after the treatments using Laemmli buffer and subjected to Western blot analysis as described (Ahmed et al., 1997) . Briefly, total proteins were electrophoresed in SDS -PAGE, transferred to membrane. After blocking by milk, the membrane was incubated in a milk solution containing p21 antibody (sc-817) (Santa Cruz, CA, USA); Dnmt-1 antibody (Imgenex, CA, USA) or pan ras antibody (OP22, oncogene research products, Cambridge, MA, USA). The bound antigen-antibody complex was detected by secondary antibody (either monoclonalor polyclonal, depending upon primary antibody) and the chemiluminescence kit. The same membrane was used for b-actin levels detected by anti-b-actin antibody (Sigma) as an internal loading control.
32 P-reverse transcriptase-polymerase chain reaction ( 32 P -RT -PCR)
Total RNA was extracted from the cell lines by using TRIZOL reagent (Gibco-BRL, Gaithesburg, MD, USA). One microgram was reverse transcribed into cDNA using a commercially available kit (Perkin Elmer Corporation, CT, USA) according to the manufacturers' recommendations. Specific primers for TGF-bRII gene expression (polyA) sequences were as follows: sense primer, 5'-TGGAGAAA-GAATGACGAGAACA-3', anti-sense primer, 5'-AAGATG-ATGTTGTCATTGCACTC-3'. The PCR yielded 185 base pair product. The dnmt1 primers, sequences were as follows: sense primer, 5'-GATCGAATTCATGCCGGCGCGTACC-GCCCCAG-3', anti-sense primer, 5'-ATGGTGGTTTGCC-TGGTGC-3'. The PCR yielded a 500 base pair product. Primers for human G6PD gene used as an internal control to normalize the expression levels.
Transient transfection and luciferase assay
TGF-b responsive promoter activity was measured using the p3TP-Luciferase assay (Wrana et al., 1994) . The p3TP-luciferase and pRL-TK control vector (Promega, WI, USA) were transiently co-transfected by Lipofectamine PLUS (Gibco -BRL), according to the manufacturers' directions. Twenty-four hours post transfection the cells remained untreated or treated with irradiation, FTI alone, in combination or with anti-TGF-b antibody. Twenty-four hours post treatment the cells and untreated controls were lysed in reporter lysis buffer and subjected to three freezethaw cycles. The activity of luciferase was measured using a Dual-Luciferase Reporter assay (Promega, WI, USA) and expressed as a ratio of p3TP/pRL -TK for normalization.
Chloramphenicol acetyl transferase (CAT) assays
RII promoter-CAT constructs were as described previously (Bae et al., 1995) . As a control, MIA PaCa-2 cells were transfected with a positive control vector (pCAT-control, Promega, Madison, WI, USA) to monitor the general transcriptional activity. Transfections were performed by the calcium phosphate co-precipitation method and 20 h post transfection treated accordingly with FTI. Cells were harvested after 24 h of treatment and normalized by the b-gal activity and standard CAT-assays were performed by using thin layer chromatography as described previously (JoshiBarve et al., 1993; Sells et al., 1995) .
